Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy

Blood Adv. 2024 May 28;8(10):2327-2331. doi: 10.1182/bloodadvances.2024012573.
No abstract available

MeSH terms

  • Adult
  • Antigens, CD19* / immunology
  • Female
  • Humans
  • Immunotherapy, Adoptive* / adverse effects
  • Immunotherapy, Adoptive* / methods
  • Male
  • Middle Aged
  • Neoplasms / immunology
  • Neoplasms / therapy
  • Neoplasms, Second Primary / etiology
  • Neoplasms, Second Primary / therapy
  • Receptors, Chimeric Antigen